List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6274774/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
3	Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1428-1441.	1.8	137
4	Peripheral Oxidative Damage in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 117-128.	1.2	133
5	Association of Cerebral Amyloid-Î ² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
6	Metabolic Alterations Induced by Sucrose Intake and Alzheimer's Disease Promote Similar Brain Mitochondrial Abnormalities. Diabetes, 2012, 61, 1234-1242.	0.3	129
7	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
8	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
9	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
10	Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiology of Aging, 2016, 41, 200.e1-200.e5.	1.5	96
11	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
12	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. Molecular Neurobiology, 2016, 53, 2189-2199.	1.9	80
13	Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scandinavian Journal of Gastroenterology, 2008, 43, 95-102.	0.6	79
14	Oxidative Damage and Progression to Alzheimer's Disease in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 1165-1177.	1.2	78
15	Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 91.	3.0	78
16	Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiology of Disease, 2013, 49, 1-12.	2.1	76
17	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
18	Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2018, 10, 33.	3.0	63

#	Article	IF	CITATIONS
19	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.4	61
20	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
21	Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. Journal of Neurology, 2009, 256, 1540-1550.	1.8	48
22	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. Current Alzheimer Research, 2012, 9, 881-889.	0.7	48
23	Development of a Mitochondriotropic Antioxidant Based on Caffeic Acid: Proof of Concept on Cellular and Mitochondrial Oxidative Stress Models. Journal of Medicinal Chemistry, 2017, 60, 7084-7098.	2.9	47
24	Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductase. FEBS Open Bio, 2012, 2, 119-128.	1.0	43
25	Differentiation-Dependent Doxorubicin Toxicity on H9c2 Cardiomyoblasts. Cardiovascular Toxicology, 2012, 12, 326-340.	1.1	39
26	Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers. Frontiers in Neurology, 2015, 6, 153.	1.1	38
27	Prognosis of Early-Onset vs. Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors. Geriatrics (Switzerland), 2016, 1, 11.	0.6	38
28	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
29	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
30	Prodromal Metabolic Phenotype in MCI Cybrids: Implications for Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 180-190.	0.7	30
31	Progranulin Peripheral Levels as a Screening Tool for the Identification of Subjects with Progranulin Mutations in a Portuguese Cohort. Neurodegenerative Diseases, 2014, 13, 214-223.	0.8	28
32	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels inÂPatients with Alzheimer's Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078.	1.2	28
33	Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cells. Oncotarget, 2015, 6, 17081-17096.	0.8	28
34	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
35	Cerebrospinal fluid AÎ ² 40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. Journal of the Neurological Sciences, 2015, 358, 308-316.	0.3	25
36	Sporadic Creutzfeldt–Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3γ assay. Neuroscience, 2016, 322, 398-407.	1.1	25

#	Article	IF	CITATIONS
37	Rapeseed oil-rich diet alters hepatic mitochondrial membrane lipid composition and disrupts bioenergetics. Archives of Toxicology, 2013, 87, 2151-2163.	1.9	22
38	Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. Epilepsy and Behavior, 2019, 98, 207-209.	0.9	22
39	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	0.9	21
40	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology, 2019, 56, 2811-2821.	1.9	20
41	Estimates of Geriatric Delirium Frequency in Noncardiac Surgeries and Its Evaluation Across the Years: A Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association, 2021, 22, 613-620.e9.	1.2	20
42	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 2.	3.0	19
43	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
44	Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2019, 67, 725-735.	1.2	18
45	Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells. Autophagy, 2020, 16, 313-333.	4.3	18
46	C-reactive protein as a predictor of mild cognitive impairment conversion into Alzheimer's disease dementia. Experimental Gerontology, 2020, 138, 111004.	1.2	18
47	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain, 2022, 145, 700-712.	3.7	16
48	Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis. Molecular Carcinogenesis, 2017, 56, 130-148.	1.3	15
49	Multiple sclerosis: Association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease. Multiple Sclerosis and Related Disorders, 2017, 11, 71-76.	0.9	15
50	Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon's Syndrome of Unknown Cause. Cerebrovascular Diseases, 2018, 46, 257-264.	0.8	15
51	Sex-dependent vulnerability of fetal nonhuman primate cardiac mitochondria to moderate maternal nutrient reduction. Clinical Science, 2021, 135, 1103-1126.	1.8	15
52	The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence. Biomedicines, 2022, 10, 315.	1.4	15
53	Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. Neuroscience Letters, 2017, 641, 101-106.	1.0	14
54	Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia. European Journal of Neurology, 2022, 29, 36-46.	1.7	14

#	Article	IF	CITATIONS
55	Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes. Current Neurovascular Research, 2010, 7, 288-300.	0.4	14
56	Mitochondriotropic antioxidant based on caffeic acid AntiOxCIN4 activates Nrf2-dependent antioxidant defenses and quality control mechanisms to antagonize oxidative stress-induced cell damage. Free Radical Biology and Medicine, 2022, 179, 119-132.	1.3	14
57	Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2020, 21, 8680.	1.8	13
58	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
59	Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. European Journal of Clinical Pharmacology, 2006, 62, 737-742.	0.8	11
60	Sub-chronic administration of doxorubicin to Wistar rats results in oxidative stress and unaltered apoptotic signaling in the lung. Chemico-Biological Interactions, 2010, 188, 478-486.	1.7	11
61	Neuropsychological profile of amyloidâ€positive versus amyloidâ€negative amnestic Mild Cognitive Impairment. Journal of Neuropsychology, 2021, 15, 41-52.	0.6	11
62	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
63	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. Journal of Alzheimer's Disease, 2018, 64, S647-S657.	1.2	10
64	Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes. Current Neurovascular Research, 2014, 11, 330-339.	0.4	9
65	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. Biomolecules, 2019, 9, 800.	1.8	8
66	CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt–Jakob disease suspected cases with inconclusive 14-3-3 result. Journal of Neurology, 2016, 263, 1847-1861.	1.8	7
67	Phytoestrogen coumestrol improves mitochondrial activity and decreases oxidative stress in the brain of ovariectomized Wistar-Han rats. Journal of Functional Foods, 2017, 34, 329-339.	1.6	7
68	Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 61, 1097-1105.	1.2	7
69	The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders, 2018, 46, 42-49.	0.7	6
70	A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia. Journal of Neurology, 2020, 267, 2567-2581.	1.8	6
71	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 785-796.	1.2	6
72	DNA Methylation Is Correlated with Oxidative Stress in Myelodysplastic Syndrome—Relevance as Complementary Prognostic Biomarkers. Cancers, 2021, 13, 3138.	1.7	6

#	Article	IF	CITATIONS
73	Variant Creutzfeldt Jacob disease: the second case in Portugal and in the same geographical region. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 180-182.	0.9	4
74	A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson's disease potential biomarkers. Translational Neurodegeneration, 2020, 9, 11.	3.6	4
75	Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis. Journal of Neuroinflammation, 2022, 19, 44.	3.1	4
76	Lower CSF Amyloid-Beta1–42 Predicts a Higher Mortality Rate in Frontotemporal Dementia. Diagnostics, 2019, 9, 162.	1.3	3
77	Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. Brain Communications, 2020, 2, fcaa126.	1.5	3
78	Neuropsychological features of progranulin-associated frontotemporal dementia: a nested case-control study. Neural Regeneration Research, 2021, 16, 910.	1.6	3
79	Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients. Frontiers in Cell and Developmental Biology, 2021, 9, 701328.	1.8	3
80	Redox profiles of amyotrophic lateral sclerosis lymphoblasts with or without known SOD1 mutations. European Journal of Clinical Investigation, 2022, 52, e13798.	1.7	3
81	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. Alzheimer's Research and Therapy, 2022, 14, 9.	3.0	2
82	Lewy body dementia is associated with an increased risk of atrial fibrillation: A case-control study. Journal of Clinical Neuroscience, 2022, 99, 62-65.	0.8	2
83	Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum. Frontiers in Neurology, 0, 13, .	1.1	2
84	Sporadic Creutzfeldt-Jakob disease causing a 2-years slowly progressive isolated dementia. Behavioural Neurology, 2009, 21, 175-9.	1.1	1
85	Cognitive Trajectories Following Acute Infection in Older Patients With and Without Cognitive Impairment: An 1-Year Follow-Up Study. Frontiers in Psychiatry, 2021, 12, 754489.	1.3	1
86	P1â€280: CEREBROSPINAL FLUID Aβ42 AND TAU MEASUREMENT ON LUMIPULSE® G: ANALYTICAL VERIFICATIO AND METHOD COMPARISON. Alzheimer's and Dementia, 2018, 14, P390.	DN _{0.4}	0
87	APOE ɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 587-601.	1.2	0